MARKET

NRBO

NRBO

NeuroBo Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.170
+0.050
+4.46%
After Hours: 1.140 -0.03 -2.56% 19:41 01/24 EST
OPEN
1.230
PREV CLOSE
1.120
HIGH
1.230
LOW
1.080
VOLUME
2.29M
TURNOVER
--
52 WEEK HIGH
6.57
52 WEEK LOW
1.080
MARKET CAP
31.11M
P/E (TTM)
-0.7003
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 13h ago
28 Stocks Moving in Monday's Pre-Market Session
Gainers BT Brands, Inc. (NASDAQ: BTBD) shares rose 158% to $6.37 in pre-market trading after declining around 12% on Friday.
Benzinga · 15h ago
Plus Therapeutics, NLS Pharmaceutics top healthcare gainers; AVROBIO, Genprex amid losers
Gainers: Plus Therapeutics PSTV +67%; NLS Pharmaceutics NLSP +31%. NeuroBo Pharmaceuticals (NASDAQ:NRBO) +29%. Immix Biopharma IMMX +23%. iSpecimen Inc. (NASDAQ:ISPC) +15%. Losers: AVROBIO (NASDAQ:AVRO) -32%; Genprex (NASDAQ:GNPX) -20%. Valneva SE American...
Seekingalpha · 01/04 15:03
Healthcare names dominate premarket losers list
Plus Therapeutics (NASDAQ:PSTV) +76% after meeting two significant milestones as it progresses toward cGMP manufacture of Rhenium-186 NanoLiposome. Immix Biopharma (NASDAQ:IMMX) +31%. Cullinan Oncology (NASDAQ:CGEM) +21% on FDA Breakthrough Therapy tag for...
Seekingalpha · 01/04 13:19
21 Stocks Moving in Wednesday's Pre-Market Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) rose 95.5% to $2.19 in pre-market trading after surging 43% on Tuesday.
Benzinga · 12/29/2021 11:40
NeuroBo Pharmaceuticals EPS beats by $0.02
NeuroBo Pharmaceuticals (NASDAQ:NRBO): Q3 GAAP EPS of -$0.16 beats by $0.02. Cash and cash equivalents of $7M Press Release
Seekingalpha · 11/15/2021 13:57
BRIEF-Neurobo Pharmaceuticals Reports 16 Cents Q3 Loss Per share
reuters.com · 11/15/2021 13:18
NeuroBo Pharmaceuticals Q3 EPS $(0.16) Up From $(0.19) YoY
NeuroBo Pharmaceuticals (NASDAQ:NRBO) reported quarterly losses of $(0.16) per share. This is a 15.79 percent increase over losses of $(0.19) per share from the same period last year.
Benzinga · 11/15/2021 13:09
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NRBO. Analyze the recent business situations of NeuroBo Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NRBO stock price target is 16.00 with a high estimate of 16.00 and a low estimate of 16.00.
High16.00
Average16.00
Low16.00
Current 1.170
EPS
Actual
Estimate
-0.96-0.72-0.48-0.24
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 36
Institutional Holdings: 3.43M
% Owned: 12.89%
Shares Outstanding: 26.59M
TypeInstitutionsShares
Increased
5
33.30K
New
2
43.35K
Decreased
8
14.67K
Sold Out
11
171.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.12%
Pharmaceuticals & Medical Research
-0.55%
Key Executives
Non-Executive Chairman/Independent Director
Andrew Koven
President/Chief Executive Officer
Gil Price
Chief Operating Officer/Senior Vice President
Akash Bakshi
Senior Vice President
Andrew Bartynski
Senior Vice President
Nadja Mannowetz
Director
jeong Gu Kang
Director
Na Yeon Kim
Independent Director
Jason Groves
Independent Director
Hyung Kim
Independent Director
Michael Salsbury
No Data
About NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development and commercialization of therapeutics. It is focused on four therapeutics programs designed to impact a range of indications in viral, neurodegenerative and cardiometabolic disease. The Company’s therapeutics programs include ANA001, NB-01, NB-02 and Gemcabene. Its ANA001, is an oral niclosamide formulation and was developed as a treatment for patients with moderate coronavirus disease (COVID-19). NB-01, which is primarily focused on the development of a treatment for painful diabetic neuropathy and treat a range of neuropathic conditions. Its NB-02, which treats the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of a protein called tau, and with amyloid beta plaque deposition. The Company’s Gemcabene, which is being assessed as an acute indication for COVID-19 treatments.

Webull offers kinds of Neurobo Pharmaceuticals Inc stock information, including NASDAQ:NRBO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NRBO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NRBO stock methods without spending real money on the virtual paper trading platform.